Mach7 Technologies (M7T) AGM 2025 summary

Opening remarks and agenda

• Meeting formally opened with quorum confirmed; directors, executive team, and auditors introduced.

• Chairman and CEO delivered addresses outlining the meeting's agenda and strategic direction.

• Agenda included business overview, FY 2025 results, FY 2026 focus, formal resolutions, and Q&A.

Financial performance review

• FY 2025 revenue reached AUD 33.8 million, up 16% from prior year, with recurring revenue at AUD 25.3 million (75% of total revenue).

• Operating expenses were AUD 31.8 million, up 9%, in line with guidance; recurring revenue covered 80% of operating expenses.

• Contracted ARR was AUD 30.2 million, up 8%; company achieved positive operating cash flow and ended with AUD 23.1 million cash, no debt.

• Profitability achieved (excluding amortization) with net profit after tax of AUD 0.4 million, reversing prior year loss; adjusted EBITDA at -AUD 0.3 million.

• On-market share buyback utilized AUD 2.2 million to acquire 6.3 million shares; buyback paused pending strategic review.

Board and executive committee updates

• CEO transition completed: Teri Thomas appointed, bringing healthcare technology and executive experience.

• Leadership renewal with new CFO and EVP of sales appointed in September 2025 to drive growth and operational efficiency.

• Founder re-engaged to accelerate growth in Asia.

• Leadership team renewed, customer-centric operating model introduced, and global resource allocation optimized.

• Board remains focused on prudent capital management and long-term value creation.